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Aims The aim of this study was to elucidate the signalling pathways implicated in the modulation of cardiac L-type Ca2+
channels by urocortin (Ucn) in ventricular myocytes.
Methods
and results
Adult rat ventricular myocytes were stimulated in vitro with Ucn for 20–40 min. L-type calcium currents (ICaL) were
measured with the patch-clamp technique, whereas quantification of activation of extracellular signal-regulated
kinases 1/2 (ERK1/2) was assessed by sandwich-ELISA. Ucn induced a significant increase in ICaL density that was
not prevented by the protein kinase A (PKA) inhibitor KT-5720 or the non-selective antagonist of guanine nucleotide
exchange factor brefeldin A. The Ucn effect was antagonized by astressin, a corticotropin-releasing factor receptor-2
(CRF-R2) antagonist, and significantly reduced by protein kinase C (PKC) and ERK1/2 inhibitors. The cyclic AMP
(cAMP) analogue 8-pCPT-2′OMe-cAMP, which selectively activates the exchange protein activated by cAMP
(Epac), was ineffective in modifying ICaL. Analysis of phospho-ERK1/2 showed that Ucn induced a significant activation
of the ERK1/2 pathway in ventricular myocytes and this effect was prevented by pre-incubation with PKC inhibitors.
Conclusion The present study provides evidence of new mechanisms involved in the modulation of L-type Ca2+ channels by Ucn
in adult ventricular myocytes. We propose that the marked increase in ICaL density induced by Ucn is mediated
through CRF-R2 and involves PKC-dependent activation of the ERK1/2 pathway, whereas PKA and Epac signalling
are not implicated.
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1. Introduction
Urocortins (Ucn) (I, II, and III) are endogenous peptides, members of
the corticotropin-releasing factor (CRF) family, that bind to
G-protein-coupled receptors (CRF-R) 1 and 2.1 –4 In the heart, only
CRF-R2 is expressed, and several studies have demonstrated that
Ucn binding to these receptors exerts beneficial action on the myo-
cardium that might have a therapeutic potential in some pathological
conditions, including human heart failure.5 –7 In vivo, Ucn is able to
induce coronary vasodilatation and it increases cardiac output and
heart rate.8,9 Ucn has been shown to possess potent and long-lasting
inotropic properties in healthy and failing animals10,11 which have
been postulated to be dependent on CRF-R2 but independent of
b-adrenergic receptors.12 In vitro, Ucn protects the heart from ischae-
mia and reperfusion injury.13,14 Many signalling pathways have been
shown to be involved in the effects of Ucn on the heart, including
phosphoinositide-3-kinase (PI3K), protein kinase A (PKA), protein
kinase B/Akt, protein kinase C (PKC), and mitogen-activated protein
kinases (MAPKs).15–17
Recently, we have reported in ex vivo Langendorff-perfused rat
hearts that the positive inotropic effect induced by Ucn was mediated
through a PKA-independent mechanism that implicated the activation
of PKC and MAPK subfamily extracellular signal-regulated kinases 1/2
(ERK1/2) and the activation of the exchange protein activated by
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cyclic AMP (Epac).18 In the same study, Ucn was reported to enhance
L-type calcium current (ICaL), although the precise mechanism
involved was not addressed.
Ca2+ entry through the L-type Ca2+ channels (ICaL) is critical in the
control of cardiac function. ICaL contributes to physiological frequency
regulation in the sinus node,19 it is an important parameter for the
duration of the plateau phase of the action potential and refractori-
ness, and plays a fundamental role in the process of Ca2+ release
from the sarcoplasmic reticulum, raising free intracellular Ca2+ con-
centration [Ca2+]i and allowing cell contraction.
20 Moreover, it is
also clear that [Ca2+]i serves as an important second messenger in
the regulation of gene expression in life-threatening cardiac diseases.21
Little information is available for the mechanism involved in the
effect of Ucn on ICaL in the heart.
18,22,23 Therefore, the present
study was undertaken to further elucidate the signalling pathways
implicated in cardiac L-type Ca2+ channel modulation by Ucn in
adult rat ventricular myocytes.
2. Methods
An expanded Methods section detailing protocols and solutions used in
this study can be found in the Supplementary material online.
2.1 Isolation of ventricular myocytes
All the experiments were performed in accordance with the animal care
guidelines of the European Communities Council (86/609/EEC), and this
study conforms to the Guide for the Care and Use of Laboratory
Animals published by the US National Institute of Health (NIH Publication
No. 85-23, revised 1996). All procedures were approved by the Bioethical
Committee of the Complutense University of Madrid. Ventricular myo-
cytes were isolated from the hearts of adult male Wistar rats (250–
300 g of weight), as described previously.24
2.2 Electrophysiological recording technique
Electrophysiological experiments were performed at room temperature
(24–268C) on Ca2+-tolerant rod-shaped ventricular myocytes. Conven-
tional whole-cell and perforated patch-clamp recordings were performed
to measure ICaL.
In a previous study, we have demonstrated in ex vivo perfused heart that
Ucn induced a positive inotropic effect with a slow time course that began
within 5 min, peaked between 20 and 30 min, and was still significantly
high 40 min after Ucn application.18 In order to analyse the effect of
Ucn on ICaL during a similar time course, but avoiding the presence of
ICaL rundown during prolonged whole-cell recordings,
25 ICaL was obtained
in ventricular myocytes incubated with vehicle or with Ucn for 20–
40 min.
In addition, we carried out a group of experiments using the perforated
patch-clamp technique that minimize current rundown to record the time
course of the effect of Ucn and isoproterenol (ISO) on ICaL.
2.3 PKA activity assay
The Kinase-Glow Luminescent Kinase Assay (Promega) was used to
measure the PKA activity in homogenates from isolated cardiomyocytes
according to the manufacturer’s instructions and as described pre-
viously.18 The activity is expressed as RLU-1 (relative light units)/
amount of protein.
2.4 Quantification of phospho-ERK1/2
by sandwich-ELISA
For the quantification of phospho-ERK (P-ERK) expression, we used the
sandwich-ELISA from R&D Systems, Inc., Minneapolis R&D (SUV1018)
as indicated previously and according to the manufacturer’s instructions.26
2.5 Drugs and statistical analysis
Drugs were purchased from Sigma, Promega, and Invitrogen. Ucn (rat) is a
synthetic peptide purchased from Sigma. Data are presented as means+
SEM. Statistical significance was evaluated by one-way ANOVA followed
by the Newman–Keuls multiple comparison tests. A value of P, 0.05
was considered significant.
3. Results
3.1 Ucn increases ICaL density in rat
ventricular myocytes
Figure 1A shows representative examples of ICaL density traces
obtained in three independent myocytes. The upper panel shows
ICaL traces obtained in a control myocyte. The middle panel shows
higher values of ICaL density obtained in one myocyte incubated
30 min with 100 nM Ucn and the bottom panel illustrates ICaL
traces obtained in one ventricular myocyte pre-incubated for
15 min with the CRF-R2 antagonist astressin (0.5 mM) and then
treated for 30 min with Ucn. ICaL traces in this myocyte were
similar to those obtained in control myocytes. Figure 1B illustrates
the current density–voltage relations from 18 control myocytes (non-
treated, open circles), 19 ventricular myocytes incubated with 100 nM
Ucn (closed circles) and from nine myocytes pre-incubated for 15 min
with 0.5 mM astressin and then treated with Ucn (closed squares). ICaL
density was significantly higher in cells treated with Ucn (closed
circles) compared with control cells (open circles). The presence of
the CRF-R2 antagonist astressin (closed squares) prevented the
effect of Ucn on ICaL density. The maximum value of ICaL density in
control was obtained at 0 mV (211.1+0.7 pA/pF), whereas in the
presence of Ucn, the maximum value of ICaL density was observed
at 210 mV (216.8+1.4 pA/pF). The bar graph in Figure 1C shows
the concentration dependence of the effect of Ucn on ICaL. Ventricu-
lar myocytes were exposed to vehicle (control) or to four different
concentrations of Ucn, 10, 50, 70, and 100 nM for 20–40 min, and
ICaL was recorded at 210 mV. The bar graph shows the percentage
of ICaL increase induced by Ucn with respect to the control group
in cells exposed to 10 nM (102.2+8.6%, n ¼ 6), 50 nM (114.1+
13.7%, n ¼ 6), 70 nM (135.2+25.5%, n ¼ 7), and 100 nM (154.5+
13.4%, n ¼ 19) of Ucn.
The voltage dependence of ICaL activation and inactivation was also
measured in control (open circles) and in Ucn-treated myocytes
(closed circles). Similar values for half-maximal activation and inacti-
vation voltage (V50) and slope factor (k) were obtained in both
groups (see Supplementary material online, Figure S1A). In addition,
the time course for activation of ICaL was analysed by measuring the
time to peak and, the time course for inactivation by analysing the
decay of ICaL as shown in Supplementary material online, Figure S1C.
The time to peak obtained at 210 mV was similar in both groups.
The decay of ICaL was best fitted by a bi-exponential model and non-
significant differences were observed when both experimental groups
were compared (see Supplementary material online, Figure S1B).
3.2 Signalling pathways involved in the
Ucn-induced increase in ICaL density
3.2.1 cAMP/PKA pathway
Ucn binds to CRF-R2, which couples to Gs–cAMP–PKA signal-
ling.27,28 Therefore, we examined whether Ucn action is mediated
by the activation of PKA. We assayed the activity of PKA in isolated
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ventricular myocytes treated 10 min with Ucn 100 nM. Figure 2A illus-
trates that Ucn increased PKA activity and this effect was largely inhib-
ited by the PKA inhibitor KT-5720. To explore the implication of PKA
in the modulation of Ucn on ICaL, ventricular myocytes were pre-
incubated for 15 min with KT-5720 (1 mM) and then exposed to
Ucn 100 nM. The upper panel in Figure 2C shows representative
ICaL traces obtained at 210 mV in two different myocytes. In the
presence of the PKA inhibitor KT-5720, Ucn induced a significant
increase in ICaL. Figure 2B summarizes the mean values of ICaL
density obtained at 210 mV in control cells, in cells incubated with
KT-5720, in cells pre-treated with KT-5720 and then exposed to
Ucn 100 nM, and in cells only treated with Ucn 100 nM. Mean
values of ICaL density obtained in ventricular myocytes pre-treated
with KT-5720 (210.6+ 1.5 pA/pF, n ¼ 11) were similar to those
obtained in control myocytes (210.9+0.6 pA/pF, n ¼ 18). In the
presence of KT-5720, Ucn induced a significant increase in ICaL
(215.5+0.8 pA/pF, n ¼ 12) which was independent of PKA acti-
vation. In order to further demonstrate that KT-5720 effectively
blocks PKA activity in our experimental conditions, ventricular
myocytes were incubated 20–40 min with the b-adrenergic
agonist, ISO 10 nM in the presence and in the absence of KT-5720
1 mM. The bottom panel in Figure 2C shows examples of ICaL traces
at 210 mV in two different myocytes. In the presence of KT-5720,
the effect of ISO on ICaL was largely inhibited. Figure 2B shows the
mean values of ICaL obtained at 210 mV in ventricular myocytes
incubated with ISO (218.9+2.7 pA/pF, n ¼ 8) and in myocytes
treated with ISO but pre-incubated with KT-5720 (211.7+1.5 pA/
pF, n ¼ 12).
It is known that ISO, through PKA activation, induces a rapid
increase in ICaL in ventricular myocytes.
29 We carried out a group
of experiments using the perforated patch configuration of the patch-
clamp technique to compare the time course of Ucn and ISO on ICaL
in ventricular myocytes. Figure 3A and B illustrates representative
experiments in which peak ICaL at 210 mV was continuously moni-
tored every 6 s. Figure 3A shows the effect of Ucn perfusion on ICaL.
Ucn was able to increase ICaL and the effect started 5 min after Ucn
application reaching a maximal level at 14–15 min. Figure 3B shows
the effect of ISO on ICaL. Application of ISO induced a very rapid
effect (,1 min) on ICaL that reached a maximal level at 3–4 min.
Similar results were obtained in other four ventricular myocytes.
3.2.2 Epac pathway
Epac belongs to a family of cAMP-regulated guanine nucleotide
exchange factors (GEFs) that mediate PKA-independent signal trans-
duction properties of the second messenger cAMP.30
In order to analyse the possible participation of the Epac pathway in
the effect of Ucn on ICaL we carried out two types of experiments. In
the first one, ventricular myocytes were pre-treated for 15 min with
brefeldin A (BFA), a non selective inhibitor of Epac,31,32 and then
treated with 100 nM Ucn. Figures 4A illustrates superimposed ICaL
Figure 1 Effects of Ucn treatment on cardiac ICaL. (A) Representative examples of ICaL obtained in three different rat ventricular cells. The upper
panel displays ICaL recordings obtained in one control cell (Cm¼ 175 pF). The middle panel shows ICaL recordings obtained in one cell treated with
100 nM Ucn (Cm ¼ 177 pF). The bottom panel displays ICaL recordings in one cell treated with Ucn (Cm ¼ 178 pF) but pre-treated with CRF-R2
receptor antagonist, astressin (0.5 mM). (B) I–V relationships for ICaL density measured in control ventricular myocytes (open circles), in ventricular
myocytes incubated, 20 min to 40 min, with 100 nM Ucn (closed circles), and in cells pre-treated with CRF-R2 receptor antagonist, astressin (0.5 mM),
and then treated with Ucn 100 nM (closed squares). When ventricular myocytes were pre-treated with astressin, the effect of Ucn on ICaL density was
prevented. (C) Concentration dependence of the Ucn-induced increase in ICaL density at 210 mV. Ventricular myocytes were exposed to four differ-
ent concentrations of Ucn, 10, 50, 70, and 100 nM. The number of cells analysed is indicated in the bar graphs. Data are given as means+ SE.
(*P, 0.05, **P, 0.01, and ***P, 0.001) vs. control.
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traces obtained at 210 mV in one myocyte treated with BFA and in
another myocyte pre-treated with BFA and then with Ucn. Under
these conditions, Ucn was able to induce a significant increase in
ICaL. Figure 4B summarizes the results obtained in 10 myocytes pre-
treated with BFA and in 14 myocytes pre-treated with BFA and
then treated with Ucn 100 nM. Mean values of ICaL density at
210 mV obtained in ventricular myocytes pre-treated with BFA
20 mM were not different (211.9+ 0.6 pA/pF, n ¼ 10) from those
obtained in control myocytes (210.9+0.6 pA/pF, n ¼ 18). In the
presence of BFA, exposure of ventricular myocytes to Ucn induced
a significant increase in ICaL density (215.6+ 0.7 pA/pF, n ¼ 14)
which suggests that BFA-sensitive pathway was not involved in the
effect of Ucn on ICaL.
In a second group of experiments, ventricular myocytes were incu-
bated for 20–40 min with the cAMP analogue 8-pCPT-2′OMe-cAMP
(8-CPT) 20 mM in the presence of KT-5720 in order to prevent any
effect of 8-CPT on PKA.33 Figure 4C shows superimposed ICaL traces
obtained at 210 mV in one control myocyte and in another myocyte
incubated with 20 mM 8-CPT + KT. Figure 4D summarizes the results
obtained in 18 control and in 13 8-CPT-treated myocytes. Mean
values of ICaL density (210.9+0.6 pA/pF, n ¼ 18) were not modified
by 8-CPT + KT (211.4+1.1 pA/pF, n ¼ 13), which suggests that the
Epac pathway is not involved in the effect of Ucn on ICaL.
3.2.3 PKC signalling
Several studies have proposed the implication of PKC activation in the
cardiac effects of Ucn.18,34 In order to analyse whether PKC contrib-
utes to the increased density of ICaL induced by Ucn in our
Figure 3 Time course of the effect of Ucn and ISO on ICaL by perfo-
rated patch-clamp recordings. The points in the figure are peak inward
currents at 210 mV every 6 s. (A) Time course of the effect of Ucn on
ICaL. The solid bar on the top indicates the time of exposure to 100 nM
Ucn. (B) Time course of the effect of ISO on ICaL. The solid bar on the
top indicates the time of exposure to 1 mM ISO.
Figure 2 Ucn increased ICaL density independentlyof PKA activation. (A) Bar graph showing the activityof PKA in control myocytes, in ventricularmyocytes
treated 10 min with Ucn 100 nM, or in ventricular myocytes pre-incubated with KT-5720 and then treated with Ucn 100 nM. (B) Bar graph showing mean
values of ICaL density measured at 210 mV in control cells, in cells incubated with KT-5720, in cells pre-treated with KT-5720 and then exposed to Ucn
100 nM or ISO 10 nM, and in cells only treated with Ucn 100 nM or ISO. (C) Upper panel: representative ICaL traces obtained at 210 mV in one
myocyte pre-treated with the PKA inhibitor KT-5720 1 mM and in another myocyte pre-treated 15 min with KT-5720 and then 35 min with Ucn. In the
presence of the PKA inhibitor, Ucn induced a significant increase in ICaL. Bottom panel: representative ICaL traces obtained at 210 mV in one myocyte incu-
bated with ISO and in another myocyte pre-treated 15 min with KT-5720 and then 25 min with ISO 10 nM. The effect of ISO on ICaL was significantly reduced
in the presence of the PKA inhibitor KT-5720. The number of cells analysed is indicated in the bar graphs. Data are given as means+ SE. **P, 0.001 vs.
control, +P, 0.001 vs. KT + Ucn, #P, 0.01 vs. KT 1 mM, 11P, 0.05 vs. KT 1 mM, *P, 0.01 vs. control, and 111P, 0.001 vs. KT + ISO.
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experiments, ventricular myocytes were pre-treated with the PKC
inhibitor chelerythrine (Chel). Figure 5A shows two superimposed
ICaL traces obtained at 210 mV in one myocyte pre-treated with
Chel and in another myocyte pre-treated 15 min with Chel and
then 30 min with Ucn. Under these conditions, Ucn did not affect
ICaL in myocyte pre-treated with Chel. The bar graph in Figure 5B
shows the mean values of ICaL density at 210 mV obtained in
control cells, in cells incubated with Chel, in cells pre-treated with
Chel and then exposed to Ucn 100 nM, and in cells only treated
with Ucn 100 nM. Mean values of ICaL density obtained at 210 mV
in ventricular myocytes pre-treated with Chel 3 mM were not signifi-
cantly different (211.2+1.3 pA/pF, n ¼ 13) from those obtained in
control myocytes (210.9+ 0.6 pA/pF, n ¼ 18). In the presence of
Chel, exposure of ventricular myocytes to Ucn did not induce any
effect on ICaL density (211.7+0.9 pA/pF, n ¼ 10). These results
strongly suggest that PKC signalling contributes to the Ucn-induced
increase on ICaL.
3.2.4 MAPK/ERK1/2 pathway
It has been postulated that in addition to PKC signalling, some of
the physiological effects of Ucn involved MAPK-dependent pathway,
including subfamily ERK1/2.18,35 To determine the potential
involvement of ERK1/2 in the Ucn-induced increase in ICaL, myocytes
were pre-treated with a specific inhibitor of ERK1/2, PD98059.
Figure 6A shows two superimposed ICaL traces obtained at 210 mV
in one myocyte pre-treated with 20 mM PD98059 and in another
myocyte pre-treated 15 min with PD98059 and then 35 min with
Ucn. In the presence of PD98059, the Ucn-induced increase in ICaL
was abolished. The bar graph in Figure 6B shows the mean values of
ICaL density at 210 mV obtained in control cells, in cells incubated
with PD98059, in cells pre-treated with PD98059 and then exposed
to Ucn 100 nM, and in cells only treated with Ucn 100 nM. Mean
values of ICaL density obtained in ventricular myocytes pre-treated
with 20 mM PD98059 (213.7+0.92 pA/pF, n ¼ 16) were not
significantly different from those obtained in control myocytes
(210.9+0.6 pA/pF, n ¼ 18). In the presence of PD98059, ventricular
myocyte exposure to Ucn did not induce a significant change in ICaL
density (211.9+1.1 pA/pF, n ¼ 17), indicating the important role
of ERK1/2 in the Ucn-induced increase in ICaL.
The next step in proving the contribution of ERK1/2 signalling in the
Ucn-induced increase in ICaL density was to investigate the activation
of ERK1/2 by Ucn. Figure 7A shows relative values of P-ERK in ventri-
cular myocytes. Ucn promoted an increase in phosphorylation of
ERK1/2 that was maximal at 5 min and remained elevated for
20 min of Ucn exposition. This increase in ERK1/2 activation was pre-
vented in myocytes pre-treated with the inhibitor of ERK1/2,
PD98059 but also by Chel the inhibitor of PKC as illustrated in
Figure 7B. These results point out that activation of ERK1/2 by Ucn
requires PKC activity in ventricular myocytes.
4. Discussion
The present study provides new insights into potential mechanisms
linking modulation of L-type Ca2+ channels by Ucn in adult ventricular
myocytes.
Phosphorylation of channel-forming subunits by different kinases is
one of the most important ways to change the activity of L-type Ca2+
channels. The stimulation of cardiac b-adrenergic receptors and
Figure 4 The Epac is not involved in the increase in ICaL density induced by Ucn. (A) Superimposed ICaL traces obtained at 210 mV in one myocyte
pre-treated with the small GEF antagonist BFA 20 mM and in another myocyte pre-treated with BFA plus Ucn 100 nM. (B) Bar graph showing mean
values of ICaL density measured at 210 mV in control cells, in cells incubated with BFA, in cells pre-treated with BFA and then exposed to Ucn
100 nM, and in cells only treated with Ucn 100 nM. (C) Superimposed ICaL traces obtained at 210 mV in one myocyte control and in another
myocyte treated 20–40 min with the Epac agonist 20 mM 8-CPT + 1 mM KT-5720. (D) Bar graph showing mean values of ICaL density measured
at 210 mV in control cells and in cells incubated with 8-CPT. The number of cells analysed is indicated in the bar graphs. Data are given as
means+ SE. **P, 0.001 vs. control, #P, 0.05 vs. BFA 20 mM, 11P, 0.05 vs. BFA 20 mM, and *P, 0.01 vs. control.
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activation of PKA are the main and most explored ways for Ca2+
channel activation.36 In our study, pharmacological inhibition of the
cAMP/PKA pathway failed to prevent the effect of Ucn on ICaL. In
addition, the time course of the effect of Ucn on ICaL was showed
to be slower than the time course of ISO on ICaL, suggesting that
Ucn via CRF-R2 can enhance ICaL through alternative pathways.
Our results differ from those reported in rabbit ventricular myo-
cytes.23 In that study, the increase in ICaL induced by Ucn was hypoth-
esized to involve PKA signalling, although the slow time course of Ucn
effect (the maximum effect was reached after 15 min of Ucn per-
fusion) prompted the authors to hypothesize that other pathways
with slower time courses for activation could participate in the
effect of Ucn on ICaL. Murata et al.
29 have demonstrated that cardio-
myocytes incubated for 10–30 min with leukaemia inhibitory factor
(LIF), a member of the interleukin-6 family, showed a significant
increase in ICaL that was independent of the cAMP/PKA pathway,
and the time course of which was similar to Ucn effect on ICaL. Pre-
treatment with PD98059 completely blocked the effect of LIF on ICaL,
which confirms the role of MAPK/ERK pathway in the modulation of
ICaL by LIF. More recently, Takahashi et al.
37 have demonstrated that
LIF, via ERK activation, phosphorylates the a1c subunit (Cav1.2) of
the L-type Ca2+ channel, in a different serine than the one targeted
by PKA, causing ICaL increase. In the present study, we have shown
that Ucn is able to activate ERK1/2 in ventricular myocytes. Further-
more, specific inhibition of ERK1/2 completely prevented
Ucn-induced increase in ICaL in cardiac myocytes, which strongly
suggests that phosphorylation of L-type Ca2+ channels by ERK
might be the mechanism involved in the potentiation of ICaL by
Ucn. Moreover, the present study revealed that PKC activation is a
previous step in the mechanism of Ucn induced ERK1/2 activation
in cardiac myocytes. The regulation of L-type Ca2+ channels by
PKC is well documented36 and there is evidence for crosstalk with
other signalling pathways. In human atrial myocytes, tyrosine kinase
stimulates ICaL only after PKC is activated.
38 In the human pregnant
myometrium, Ucn, via CRF-R1 and -R2, stimulates Gq with sub-
sequent production of inositol trisphosphates (IP3) and PKC acti-
vation, which correlated with MAPK/ERK phosphorylation.39 In
cardiomyocytes, activation of ERK1/2 by platelet-derived growth
factor required PKC activity.40 The mechanism by which PKC might
directly activate the MAPK/ERK pathway and activate L-type Ca2+
channels cascade in cardiac myocytes treated with Ucn remains
unclear. There is evidence that MAPK/ERK regulates the Kv4.2
Figure 5 PKC inhibition prevented the increase in ICaL density
induced by Ucn. Myocytes were pre-treated with the PKC inhibitor
Chel 3 mM and then incubated (20–40 min) with Ucn 100 nM. (A)
Representative ICaL traces obtained at 210 mV in one myocyte pre-
treated with Chel and in another myocyte pre-treated 15 min with
Chel and then 35 min with Ucn. (B) Bar graph showing mean
values of ICaL density measured at 210 mV in control cells, in cells
incubated with Chel, in cells pre-treated with Chel and then
exposed to Ucn 100 nM, and in cells only treated with Ucn
100 nM. The number of cells analysed is indicated in the bar graph.
Data are given as means+ SE. **P, 0.01 vs. control, #P, 0.01
vs. Chel + Ucn, and 11P, 0.01 vs. Chel 3 mM.
Figure 6 MAPK/ERK inhibition prevented the effect of Ucn on ICaL
density. Cells were pre-treated with the ERK1/2 inhibitor PD98059
20 mM and then incubated (20–40 min) with Ucn 100 nM. (A)
Superimposed ICaL traces obtained at 210 mV in one myocyte pre-
treated with PD98059 and in another myocyte pre-treated 15 min
with PD98059 and then treated 35 min with Ucn. (B) Bar graph
showing mean values of ICaL density measured at 210 mV in
control cells, in cells incubated with PD98059, in cells pre-treated
with PD98059 and then exposed to Ucn 100 nM, and in cells only
treated with Ucn 100 nM. The number of cells analysed is indicated
in the bar graph. Data are given as means+ SE. **P, 0.01 vs.
control, #P, 0.01 vs. PD98059 + Ucn, and 11P, 0.05 vs.
PD98059.
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potassium channels by direct phosphorylation of the pore-forming
subunit41 and phosphorylation of Kv4.2 by PKC-enhanced ERK phos-
phorylation of the channel in vitro.42 A similar mechanism could be
proposed for the activation of L-type Ca2+ channels by Ucn in cardi-
omyocytes. On the other hand, it is known that Ucn binding to
CRF-R2 activates the Gs-cAMP-PKA cascade in adult cardiomyo-
cytes;18 although the results shown in the present study support
the idea that PKA is not involved in the enhancement of ICaL
induced by Ucn, we checked whether the other cAMP-binding
protein and subsequent signalling pathway might mediate the effects
of Ucn on ICaL. In this regard, a GEF directly activated by cAMP and
named Epac has been identified.30,43 There is recent information
showing that Epac pathway might participate in the regulation of
cardiac myofilament function44 and in the Ca2+ handling in cardio-
myocytes.45,46 We have proven previously that pre-treatment with
the non-selective Epac antagonist BFA largely inhibited the positive
inotropic effect of Ucn in the perfused heart.18 Moreover, it is now
recognized that Epac can mediate the cAMP-dependent regulation
of ionic channel function. For example, Epac mediated inhibition of
ATP-sensitive K+ channels (KATP channels) in pancreatic b cells,
47
and in chromaffin cells, Epac induced increase in the
low-voltage-activated T-type Ca2+ current.48 Therefore, we have ana-
lysed in the present study, the implication of BFA-sensitive pathway in
the effect of Ucn on ICaL in ventricular myocytes. Our results demon-
strated that Ucn was able to induce a significant increase in ICaL in
those myocytes pre-treated with BFA, which suggests that the BFA-
sensitive pathway is not involved in the effect of Ucn on ICaL. More-
over, to further discard the implication of Epac in the effect of Ucn
on ICaL, myocytes were pre-treated with the cAMP analogue 8-CPT
which selectively activates Epac but not PKA when it was used at
low concentrations. Our results showed that 8-CPT has no effect
on ICaL in adult ventricular myocytes and therefore confirms that
cAMP-dependent Epac activation does not modulate L-type Ca2+
channels in adult ventricular myocytes. Hence, it appears that the
positive inotropic effect induced by Ucn18 involves the activation of
two independent pathways: Epac signalling and L-type Ca2+ channels,
and in both mechanisms, PKC plays an important role (see
Supplementary material online, Figure S2). We can speculate that
the activation of different PKC isozymes could explain distinct effect
mediated by Ucn in cardiac myocytes. For example, PKC1 is impor-
tant for Epac regulation of Ca2+ signalling in the sarcoplasmic reticu-
lum.45 In our studies, we focused on the acute effect of Ucn on heart
contractility18 and L-type Ca2+ channels. However, it is important to
keep in mind that chronic activation of some PKC isozymes partici-
pate in specific aspects of cardiac remodelling and dysfunction in
heart failure, including cardiac hypertrophy.49
In conclusion, the present study provides evidence of new mechan-
isms involved in the modulation of L-type Ca2+ channels by Ucn in
adult rat ventricular myocytes. We propose that the marked increase
in ICaL density induced by Ucn is mediated through CRF-R2 and would
involve PKC-dependent activation of MAPK–ERK1/2 pathway,
whereas PKA and Epac signalling are not implicated.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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